Ubqln2 — Ubiquilin 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Gene Symbol |
UBQLN2 |
| Full Name |
Ubiquilin 2 |
| Chromosomal Location |
Xp11.23 |
| NCBI Gene ID |
29978 |
| OMIM ID |
300364 |
| Ensembl ID |
ENSG00000148120 |
| UniProt ID |
Q9UHD2 |
| Encoded Protein |
Ubiquilin-2 |
| Associated Diseases |
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Charcot-Marie-Tooth Disease |
UBQLN2 (Ubiquilin 2), located at Xp11.23, encodes a member of the ubiquilin family that plays a critical role in protein quality control. Ubiquilin-2 is highly expressed in the nervous system and is implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), particularly in families with X-linked inheritance. Pathogenic variants cause a unique form of neurodegeneration with nuclear aggregates.
The UBQLN2 gene encodes Ubiquilin-2, a 600-amino acid protein:
- Protein quality control: Shuttles ubiquitinated proteins to the proteasome
- Autophagy regulation: Mediates selective autophagy of protein aggregates
- ER-associated degradation (ERAD): Participates in ER stress response
- Synaptic function: Localizes to synapses; involved in synaptic plasticity
- DNA repair: Contributes to DNA damage response
- Stress granule dynamics: Associates with stress granules under proteotoxic stress
Ubiquilin-2 shares structural features with UBQLN1 but has a unique proline-rich region and is X-linked.
| Feature |
Details |
| Molecular weight |
~66 kDa |
| Domains |
Ubl domain (1-70), Sti1-like domains (100-350), PXXP proline-rich (350-450), UBA domain (530-600) |
| Isoforms |
Multiple isoforms |
| Post-translation |
Phosphorylation, ubiquitination |
| Tissue specificity |
Highest in brain and spinal cord |
- Inheritance: X-linked dominant
- Mechanism: Dominant-negative effect impairs protein quality control
- Variants: Missense variants (P497H, P506T, P525S) in UBA domain
- Pathology: Ubiquilin-2 positive inclusions in motor neurons
- Onset: Earlier onset than typical ALS (~40-50 years)
- Overlap: ALS-FTD spectrum
- Mechanism: Impaired clearance of TDP-43
- Pathology: Ubiquilin-2 inclusions in frontal cortex
- Inheritance: X-linked recessive
- Variants: Certain variants cause peripheral neuropathy
- Mechanism: Impaired synaptic protein quality control in peripheral nerves
- Huntington's disease: Dysregulated in HD
- Alzheimer's disease: Altered expression in AD brain
- Brain: High in motor cortex, hippocampus, basal ganglia, cerebellum
- Spinal cord: High in anterior horn cells (motor neurons)
- Cell types: Motor neurons, pyramidal neurons, glial cells
- Subcellular: Cytoplasmic; associated with ER, aggresomes, synapses
- Regulation: Stress-induced upregulation
- Allen Brain Atlas: High in cortical layers, motor neurons
- Deng et al., UBQLN2 mutations cause ALS/FTD (2011)
- Chang and Madeo, UBQLN2 in neurodegeneration (2014)
- Gerson et al., Ubiquilin-2 function in ALS (2014)
- Scotter et al., ALS-FTD genetics (2014)
- Zhang et al., UBQLN2 pathogenesis (2015)
- Proteostasis modulators: Enhance protein quality control
- Autophagy enhancers: Promote aggregate clearance
- Gene therapy: Viral vector delivery of wild-type UBQLN2
- ASO therapy: Reduce expression of mutant allele
- Understanding X-linked inheritance in ALS
- Developing small molecules targeting ubiquilin function
- Biomarker development for UBQLN2-related disease
The study of Ubqln2 — Ubiquilin 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.